Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
LTS Lohmann Therapie-Systeme AG
Andernach / Montreal (ots) - LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to provide customers with robust, reliable, high-quality ...
LAUDA DR. R. WOBSER GMBH & CO. KG
London and Boston (ots/PRNewswire) - Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines. Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company's newly ...
London (ots/PRNewswire) - Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 ...
London (ots/PRNewswire) - Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 ...
LAUDA DR. R. WOBSER GMBH & CO. KG
